Patent Application: Anti-FGFR2 Antibodies with Chemotherapy for Cancer Treatment
Summary
The USPTO has published patent application US20260085123A1, filed by Five Prime Therapeutics, Inc. The application details the use of anti-FGFR2 antibodies in combination with mFOLFOX6 chemotherapy for treating certain cancers.
What changed
This document is a published patent application (US20260085123A1) from the USPTO, filed by Five Prime Therapeutics, Inc. It describes novel uses of antibodies targeting fibroblast growth factor receptor 2 (FGFR2), specifically the FGFR2-IIIb isoform, in conjunction with mFOLFOX6 chemotherapy for the treatment of certain types of cancer.
As this is a patent application, it does not impose direct regulatory obligations on companies. However, it signifies potential future intellectual property claims and may influence research and development strategies in the oncology sector. Companies operating in drug development and cancer treatment should be aware of this filing for competitive intelligence and potential licensing considerations.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-FGFR2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY AGENTS IN CANCER TREATMENT
Application US20260085123A1 Kind: A1 Mar 26, 2026
Assignee
FIVE PRIME THERAPEUTICS, INC.
Inventors
Helen L. COLLINS, James HNATYSZYN, Hong XIANG, Xiang ZHANG
Abstract
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
CPC Classifications
C07K 16/2863 A61K 9/0019 A61K 31/282 A61K 31/513 A61K 31/519 A61K 39/00 A61K 39/3955 A61P 35/00 A61P 35/04 A61K 2039/505 A61K 2039/545 C07K 2317/41 C07K 2317/732 C07K 2317/74 C07K 2317/76 C07K 2317/92
Filing Date
2025-05-05
Application No.
19199126
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.